This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).
Severe chronic kidney disease (stage 4-5);
Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
Other non-neuroendocrine malignancies.